ECO Animal Health is proactively researching and developing innovative new solutions to enhance the lives of pigs and poultry, with a proprietary pipeline of vaccines and other assets expected to launch commercially from 2026.
ECO Animal Health’s R&D pipeline is focused on treating and preventing economically important respiratory and enteric diseases in pigs and poultry to improve their health, welfare and subsequently profitability on-farm.
Investing in preventative medicines reflects the industry trend of improving animal health and welfare by preventing disease rather than waiting to treat disease when it occurs. This enables pigs and poultry to enjoy healthier lives and delivers maximum profitability to producers.
You can hear the ECO Animal Health team talking about the company’s innovative strategy and development pipeline at our most recent R&D Day recording here.
In August 2026, ECO and Vaxinano SAS announced a license agreement for the development of Vaxinano’s sheep vaccine candidate against toxoplasmosis. The licence also provides ECO with the potential to build additional livestock vaccines over time. Read more here.
Last updated: January 2026
